See more : China Rare Earth Holdings Limited (0769.HK) Income Statement Analysis – Financial Results
Complete financial analysis of McKesson Corporation (MCK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of McKesson Corporation, a leading company in the Medical – Distribution industry within the Healthcare sector.
You may be interested
- Gores Holdings VII, Inc. (GSEVW) Income Statement Analysis – Financial Results
- Raghuvir Synthetics Limited (RAGHUSYN.BO) Income Statement Analysis – Financial Results
- UIL Finance Limited (UTLF.L) Income Statement Analysis – Financial Results
- Shanta Gold Limited (SAAGF) Income Statement Analysis – Financial Results
- 7 Acquisition Corporation (SVNAU) Income Statement Analysis – Financial Results
McKesson Corporation (MCK)
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 308.95B | 276.71B | 263.97B | 238.23B | 231.05B | 214.32B | 208.36B | 198.53B | 190.88B | 179.05B | 137.61B | 122.46B | 122.73B | 112.08B | 108.70B | 106.63B | 101.70B | 92.98B | 88.05B | 80.51B | 69.51B | 57.12B | 50.01B | 42.01B | 36.73B | 30.38B | 20.86B | 12.89B | 13.72B | 13.19B |
| Cost of Revenue | 296.37B | 264.35B | 250.84B | 226.08B | 219.03B | 202.57B | 197.17B | 187.26B | 179.47B | 167.63B | 129.30B | 115.47B | 116.17B | 106.11B | 103.03B | 101.25B | 96.69B | 88.65B | 84.19B | 77.05B | 66.26B | 54.02B | 47.21B | 39.58B | 34.21B | 27.52B | 19.25B | 11.78B | 12.50B | 12.03B |
| Gross Profit | 12.58B | 12.36B | 13.13B | 12.15B | 12.02B | 11.75B | 11.18B | 11.27B | 11.42B | 11.41B | 8.31B | 6.98B | 6.57B | 5.97B | 5.68B | 5.38B | 5.01B | 4.33B | 3.86B | 3.46B | 3.25B | 3.10B | 2.80B | 2.43B | 2.52B | 2.86B | 1.61B | 1.11B | 1.22B | 1.16B |
| Gross Profit Ratio | 4.07% | 4.47% | 4.97% | 5.10% | 5.20% | 5.48% | 5.37% | 5.68% | 5.98% | 6.37% | 6.04% | 5.70% | 5.35% | 5.33% | 5.22% | 5.04% | 4.93% | 4.66% | 4.39% | 4.30% | 4.67% | 5.43% | 5.59% | 5.79% | 6.87% | 9.43% | 7.71% | 8.61% | 8.88% | 8.82% |
| Research & Development | 179.00M | 89.00M | 70.00M | 74.00M | 96.00M | 71.00M | 125.00M | 341.00M | 392.00M | 392.00M | 456.00M | 480.00M | 440.00M | 407.00M | 376.00M | 364.00M | 347.00M | 284.00M | 223.00M | 182.00M | 172.70M | 149.40M | 135.10M | 147.50M | 112.60M | 114.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.91B | 15.55B | 21.07B | 17.70B | 18.34B | 8.40B | 8.14B | 7.47B | 7.28B | 7.90B | 5.42B | 2.35B | 3.07B | 2.76B | 2.57B | 3.08B | 3.19B | 2.79B | 2.48B | 2.27B | 2.09B | 2.02B | 1.95B | 2.08B | 2.05B | 2.22B | 1.16B | 944.50M | 872.90M | 1.12B |
| Selling & Marketing | 1.10B | -7.78B | -10.54B | -8.85B | -9.17B | -8.40B | -8.14B | -7.47B | -7.28B | -7.90B | -5.42B | 1.85B | 764.00M | 767.00M | 746.00M | 743.00M | 744.00M | 673.00M | 611.00M | 550.10M | 513.10M | 499.00M | 427.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.20B | 7.78B | 10.54B | 8.85B | 9.17B | 8.40B | 8.14B | 7.80B | 7.67B | 8.29B | 5.87B | 4.20B | 149.00M | 3.94B | 3.31B | 3.82B | 3.19B | 2.79B | 2.48B | 2.27B | 2.09B | 2.02B | 1.95B | 2.08B | 2.05B | 2.22B | 1.16B | 944.50M | 872.90M | 1.12B |
| Other Expenses | 298.00M | 497.00M | 259.00M | 223.00M | 12.00M | 182.00M | 130.00M | 90.00M | 58.00M | 63.00M | 32.00M | 10.00M | 3.21B | 2.98B | -20.00M | 3.08B | -5.00M | -6.00M | 45.00M | 1.20B | 0.00 | 0.00 | 22.00M | 111.60M | 201.30M | 199.30M | 87.20M | 71.80M | 71.30M | 69.80M |
| Operating Expenses | 8.68B | 7.78B | 10.54B | 8.85B | 9.26B | 8.47B | 8.26B | 7.80B | 7.67B | 8.29B | 5.87B | 4.68B | 4.42B | 3.94B | 3.67B | 4.18B | 3.53B | 3.07B | 2.75B | 3.66B | 2.26B | 2.17B | 2.10B | 2.33B | 2.37B | 2.53B | 1.25B | 1.02B | 944.20M | 1.19B |
| Cost & Expenses | 305.04B | 272.13B | 261.37B | 234.93B | 228.29B | 211.04B | 205.44B | 195.06B | 187.14B | 175.93B | 135.17B | 120.15B | 120.59B | 110.05B | 106.69B | 105.44B | 100.23B | 91.71B | 86.94B | 80.71B | 68.52B | 56.19B | 49.31B | 41.91B | 36.58B | 30.05B | 20.50B | 12.79B | 13.44B | 13.22B |
| Interest Income | 118.00M | 107.00M | 10.00M | 12.00M | 49.00M | 39.00M | 48.00M | 29.00M | 18.00M | 20.00M | 23.00M | 22.00M | 19.00M | 18.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 252.00M | 248.00M | 178.00M | 217.00M | 249.00M | 264.00M | 283.00M | 308.00M | 353.00M | 374.00M | 303.00M | 240.00M | 251.00M | 222.00M | 187.00M | 144.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 635.00M | 857.00M | 1.00B | 1.22B | 922.00M | 949.00M | 951.00M | 910.00M | 885.00M | 1.02B | 704.00M | 591.00M | 551.00M | 496.00M | 474.00M | 441.00M | 371.00M | 295.00M | 266.00M | 250.90M | 232.10M | 203.70M | 207.50M | 246.10M | 201.30M | 199.30M | 87.20M | 71.80M | 71.30M | 69.80M |
| EBITDA | 4.67B | 5.74B | 3.11B | -3.60B | 2.32B | 4.06B | 3.86B | 4.39B | 4.56B | 4.14B | 3.06B | 2.74B | 2.72B | 2.33B | 2.53B | 1.65B | 1.85B | 1.56B | 1.39B | 29.00M | 1.21B | 929.90M | 905.00M | 450.30M | 332.10M | 531.50M | 449.40M | 164.60M | 345.40M | 50.10M |
| EBITDA Ratio | 1.51% | 2.06% | 1.37% | 1.85% | 1.12% | 1.97% | 1.80% | 2.25% | 2.46% | 2.34% | 2.30% | 2.39% | 2.20% | 2.26% | 2.28% | 1.54% | 1.80% | 1.66% | 1.46% | 1.48% | 1.68% | 1.90% | 1.79% | 1.01% | 0.25% | 1.75% | 2.15% | 1.28% | 2.52% | 0.26% |
| Operating Income | 3.91B | 4.38B | 2.85B | 3.52B | 1.66B | 886.00M | 762.00M | 7.11B | 3.55B | 2.97B | 2.37B | 2.32B | 2.15B | 1.82B | 2.01B | 1.20B | 1.48B | 1.26B | 1.11B | -190.50M | 983.40M | 929.90M | 693.60M | 96.40M | 158.20M | 332.20M | 362.20M | 92.80M | 274.10M | -30.10M |
| Operating Income Ratio | 1.27% | 1.58% | 1.08% | 1.48% | 0.72% | 0.41% | 0.37% | 3.58% | 1.86% | 1.66% | 1.72% | 1.89% | 1.75% | 1.62% | 1.85% | 1.12% | 1.45% | 1.36% | 1.27% | -0.24% | 1.41% | 1.63% | 1.39% | 0.23% | 0.43% | 1.09% | 1.74% | 0.72% | 2.00% | -0.23% |
| Total Other Income/Expenses | -120.00M | 249.00M | -110.00M | 6.00M | -1.35B | -276.00M | -523.00M | -231.00M | -295.00M | -311.00M | -343.00M | -396.00M | -230.00M | -186.00M | -144.00M | -132.00M | -21.00M | 33.00M | 44.00M | -54.50M | -72.00M | -74.50M | -87.50M | -196.30M | 148.70M | -130.20M | -109.40M | -61.70M | -44.40M | -23.40M |
| Income Before Tax | 3.79B | 4.63B | 1.93B | -5.03B | 1.14B | 610.00M | 239.00M | 6.89B | 3.25B | 2.66B | 2.10B | 1.92B | 1.92B | 1.64B | 1.86B | 1.06B | 1.46B | 1.30B | 1.16B | -239.80M | 911.40M | 855.40M | 601.20M | 9.60M | 306.90M | 202.00M | 253.50M | 36.40M | 224.10M | -81.70M |
| Income Before Tax Ratio | 1.23% | 1.67% | 0.73% | -2.11% | 0.50% | 0.28% | 0.11% | 3.47% | 1.70% | 1.48% | 1.52% | 1.57% | 1.56% | 1.46% | 1.71% | 1.00% | 1.43% | 1.39% | 1.32% | -0.30% | 1.31% | 1.50% | 1.20% | 0.02% | 0.84% | 0.66% | 1.22% | 0.28% | 1.63% | -0.62% |
| Income Tax Expense | 629.00M | 905.00M | 636.00M | -695.00M | 18.00M | 356.00M | -53.00M | 1.61B | 908.00M | 815.00M | 742.00M | 581.00M | 516.00M | 505.00M | 601.00M | 241.00M | 468.00M | 329.00M | 421.00M | -83.10M | 264.90M | 293.30M | 182.60M | 52.30M | 122.30M | 117.10M | 98.60M | 31.30M | 88.70M | 111.50M |
| Net Income | 3.00B | 3.56B | 1.11B | -4.34B | 900.00M | 34.00M | 67.00M | 5.07B | 2.26B | 1.48B | 1.26B | 1.34B | 1.40B | 1.20B | 1.26B | 823.00M | 990.00M | 913.00M | 751.00M | -156.70M | 646.50M | 555.40M | 418.60M | -48.30M | 723.70M | 84.90M | 154.90M | 133.90M | 135.40M | 404.50M |
| Net Income Ratio | 0.97% | 1.29% | 0.42% | -1.82% | 0.39% | 0.02% | 0.03% | 2.55% | 1.18% | 0.82% | 0.92% | 1.09% | 1.14% | 1.07% | 1.16% | 0.77% | 0.97% | 0.98% | 0.85% | -0.19% | 0.93% | 0.97% | 0.84% | -0.11% | 1.97% | 0.28% | 0.74% | 1.04% | 0.99% | 3.07% |
| EPS | 22.54 | 25.23 | 7.31 | -27.02 | 4.97 | 0.17 | 0.32 | 22.95 | 9.82 | 6.37 | 5.51 | 5.71 | 5.70 | 4.65 | 4.70 | 2.99 | 3.40 | 3.06 | 2.46 | -0.53 | 2.23 | 1.92 | 1.47 | -0.17 | 2.57 | 0.31 | 1.14 | 0.83 | 1.53 | 4.60 |
| EPS Diluted | 22.39 | 25.04 | 7.23 | -27.02 | 4.95 | 0.17 | 0.32 | 22.73 | 9.70 | 6.27 | 5.41 | 5.59 | 5.59 | 4.57 | 4.62 | 2.95 | 3.32 | 2.99 | 2.38 | -0.53 | 2.19 | 1.88 | 1.43 | -0.17 | 2.55 | 0.31 | 1.10 | 0.80 | 1.45 | 4.43 |
| Weighted Avg Shares Out | 133.20M | 141.10M | 152.30M | 160.60M | 181.00M | 196.30M | 208.00M | 221.00M | 230.00M | 232.00M | 229.00M | 235.00M | 246.00M | 258.00M | 269.00M | 275.00M | 291.00M | 298.00M | 306.00M | 294.00M | 290.00M | 289.30M | 285.20M | 283.10M | 281.30M | 275.20M | 282.10M | 83.65M | 88.50M | 87.93M |
| Weighted Avg Shares Out (Dil) | 134.10M | 142.20M | 154.10M | 160.60M | 182.00M | 197.30M | 209.00M | 223.00M | 233.00M | 235.00M | 233.00M | 239.00M | 251.00M | 263.00M | 273.00M | 279.00M | 298.00M | 305.00M | 316.00M | 294.00M | 299.00M | 298.80M | 298.10M | 283.10M | 284.20M | 275.20M | 282.10M | 84.39M | 93.38M | 91.31M |
Here's Why McKesson (MCK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Stocks That Look Promising Following Broker Rating Upgrades
Investors should monitor stocks like American Airlines, Air Canada, DXC, Dollar General, and McKesson for high returns.
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in Florida Cancer Specialists enhances its oncology...
MCK Stock Gains as Q2 Earnings & Sales Top Estimates, '25 EPS View Up
McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings
McKesson MCK reported better-than-expected second-quarter financial results on Wednesday.
McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
McKesson (MCK) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
McKesson (MCK) Q2 Earnings and Revenues Beat Estimates
McKesson (MCK) came out with quarterly earnings of $7.07 per share, beating the Zacks Consensus Estimate of $6.89 per share. This compares to earnings of $6.23 per share a year ago.
McKesson raises annual profit forecast on strength in its U.S. pharma segment
Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S. pharmaceuticals segment on robust demand for specialty and branded drugs.
McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference...
Source: https://incomestatements.info
Category: Stock Reports